Last reviewed · How we verify

Bupivacaine + nalbuphine

Alzahraa Ahmed Abbas · FDA-approved active Small molecule

Bupivacaine + nalbuphine is a Local anesthetic + mixed opioid agonist-antagonist Small molecule drug developed by Alzahraa Ahmed Abbas. It is currently FDA-approved for Local anesthesia with analgesia for surgical and regional anesthetic procedures.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while nalbuphine provides opioid analgesia by acting as a mixed kappa agonist and mu antagonist.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while nalbuphine provides opioid analgesia by acting as a mixed kappa agonist and mu antagonist. Used for Local anesthesia with analgesia for surgical and regional anesthetic procedures.

At a glance

Generic nameBupivacaine + nalbuphine
SponsorAlzahraa Ahmed Abbas
Drug classLocal anesthetic + mixed opioid agonist-antagonist
TargetVoltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve cells, preventing depolarization and conduction of nerve impulses. Nalbuphine is an opioid analgesic that binds to kappa opioid receptors as an agonist and mu opioid receptors as an antagonist, providing pain relief with a lower abuse potential than pure mu agonists. The combination provides both local anesthetic and systemic analgesic effects for enhanced pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine + nalbuphine

What is Bupivacaine + nalbuphine?

Bupivacaine + nalbuphine is a Local anesthetic + mixed opioid agonist-antagonist drug developed by Alzahraa Ahmed Abbas, indicated for Local anesthesia with analgesia for surgical and regional anesthetic procedures.

How does Bupivacaine + nalbuphine work?

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while nalbuphine provides opioid analgesia by acting as a mixed kappa agonist and mu antagonist.

What is Bupivacaine + nalbuphine used for?

Bupivacaine + nalbuphine is indicated for Local anesthesia with analgesia for surgical and regional anesthetic procedures.

Who makes Bupivacaine + nalbuphine?

Bupivacaine + nalbuphine is developed and marketed by Alzahraa Ahmed Abbas (see full Alzahraa Ahmed Abbas pipeline at /company/alzahraa-ahmed-abbas).

What drug class is Bupivacaine + nalbuphine in?

Bupivacaine + nalbuphine belongs to the Local anesthetic + mixed opioid agonist-antagonist class. See all Local anesthetic + mixed opioid agonist-antagonist drugs at /class/local-anesthetic-mixed-opioid-agonist-antagonist.

What development phase is Bupivacaine + nalbuphine in?

Bupivacaine + nalbuphine is FDA-approved (marketed).

What are the side effects of Bupivacaine + nalbuphine?

Common side effects of Bupivacaine + nalbuphine include Hypotension, Bradycardia, Nausea, Dizziness, Headache, Nervousness or anxiety.

What does Bupivacaine + nalbuphine target?

Bupivacaine + nalbuphine targets Voltage-gated sodium channels (bupivacaine); kappa and mu opioid receptors (nalbuphine) and is a Local anesthetic + mixed opioid agonist-antagonist.

Related